SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) Fundamental Analysis & Valuation

FRA:PSH0 • CA81752F1062

Current stock price

0.1035 EUR
0 (0%)
Last:

This PSH0.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PSH0.DE Profitability Analysis

1.1 Basic Checks

  • PSH0 had negative earnings in the past year.
  • PSH0 had a negative operating cash flow in the past year.
  • PSH0 had negative earnings in each of the past 5 years.
  • PSH0 had a negative operating cash flow in each of the past 5 years.
PSH0.DE Yearly Net Income VS EBIT VS OCF VS FCFPSH0.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • PSH0 has a Return On Assets of -1222.61%. This is amonst the worse of the industry: PSH0 underperforms 98.73% of its industry peers.
Industry RankSector Rank
ROA -1222.61%
ROE N/A
ROIC N/A
ROA(3y)-888.07%
ROA(5y)-546.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSH0.DE Yearly ROA, ROE, ROICPSH0.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PSH0 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSH0.DE Yearly Profit, Operating, Gross MarginsPSH0.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. PSH0.DE Health Analysis

2.1 Basic Checks

  • PSH0 has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PSH0 has more shares outstanding
  • The debt/assets ratio for PSH0 is higher compared to a year ago.
PSH0.DE Yearly Shares OutstandingPSH0.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
PSH0.DE Yearly Total Debt VS Total AssetsPSH0.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -300.18, we must say that PSH0 is in the distress zone and has some risk of bankruptcy.
  • PSH0 has a worse Altman-Z score (-300.18) than 96.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -300.18
ROIC/WACCN/A
WACCN/A
PSH0.DE Yearly LT Debt VS Equity VS FCFPSH0.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 0.03 indicates that PSH0 may have some problems paying its short term obligations.
  • PSH0 has a worse Current ratio (0.03) than 98.73% of its industry peers.
  • A Quick Ratio of 0.03 indicates that PSH0 may have some problems paying its short term obligations.
  • PSH0's Quick ratio of 0.03 is on the low side compared to the rest of the industry. PSH0 is outperformed by 98.73% of its industry peers.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
PSH0.DE Yearly Current Assets VS Current LiabilitesPSH0.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PSH0.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.65% over the past year.
EPS 1Y (TTM)58.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PSH0 will show a very strong growth in Earnings Per Share. The EPS will grow by 41.92% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.94%
EPS Next 2Y28.34%
EPS Next 3Y84.06%
EPS Next 5Y41.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PSH0.DE Yearly Revenue VS EstimatesPSH0.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
PSH0.DE Yearly EPS VS EstimatesPSH0.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. PSH0.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • PSH0 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PSH0 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSH0.DE Price Earnings VS Forward Price EarningsPSH0.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSH0.DE Per share dataPSH0.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.01 -0.02 -0.03 -0.04

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PSH0's earnings are expected to grow with 84.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.34%
EPS Next 3Y84.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PSH0.DE Dividend Analysis

5.1 Amount

  • No dividends for PSH0!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PSH0.DE Fundamentals: All Metrics, Ratios and Statistics

SERNOVA BIOTHERAPEUTICS INC

FRA:PSH0 (4/10/2026, 7:00:00 PM)

0.1035

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)N/A
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners4%
Ins Owner ChangeN/A
Market Cap34.85M
Revenue(TTM)N/A
Net Income(TTM)-12.38M
Analysts80
Price Target2.13 (1957.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.74%
Min EPS beat(2)0.99%
Max EPS beat(2)50.5%
EPS beat(4)4
Avg EPS beat(4)25.74%
Min EPS beat(4)0.99%
Max EPS beat(4)50.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.15%
PT rev (3m)-0.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-14.29%
EPS NY rev (3m)47.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1222.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-888.07%
ROA(5y)-546.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z -300.18
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.34%
EPS Next Y52.94%
EPS Next 2Y28.34%
EPS Next 3Y84.06%
EPS Next 5Y41.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.69%
EBIT Next 3Y23.38%
EBIT Next 5Y40.83%
FCF growth 1Y75.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.52%
OCF growth 3YN/A
OCF growth 5YN/A

SERNOVA BIOTHERAPEUTICS INC / PSH0.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SERNOVA BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to PSH0.DE.


What is the valuation status for PSH0 stock?

ChartMill assigns a valuation rating of 1 / 10 to SERNOVA BIOTHERAPEUTICS INC (PSH0.DE). This can be considered as Overvalued.


What is the profitability of PSH0 stock?

SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) has a profitability rating of 0 / 10.


How financially healthy is SERNOVA BIOTHERAPEUTICS INC?

The financial health rating of SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) is 0 / 10.